Circular Genomics Inc.

Circular Genomics’ CircRNA blood-based biomarker platform will be featured in the oral presentation “Identifying and stratifying Alzheimer’s disease using circular RNA biomarkers in blood” at the Clinical Trials on Alzheimer’s Disease Conference on December 3rd. Read our press…

🧠 Did you know? Studies show that lifestyle changes consisting of a combination of physical activity, improving nutrition, cognitive and social challenge, and health monitoring improved cognition in older adults at risk of cognitive decline. Learn more here:…

When Debbie first noticed memory lapses, she thought it was normal aging. “Many of us want to keep our independence for as long as we can.” Her story underscores why early detection in Alzheimer’s is vital. Learn about Debbie's story: na2.hubs.ly/H020Wtr0.

Circular RNAs (circRNAs) are emerging as a powerful platform shaping the future of neurology and psychiatry. The CircRNA platform is advancing scientific and clinical innovation in offering novel pathways toward earlier disease detection & intervention, improved patient…

Alzheimer’s isn’t only a disease of old age. Younger-onset Alzheimer’s can affect people in their 40s-60s upending families and daily life. Early detection tools can give individuals and their loved ones more time, options, and support. Read Anitra's story:…

CircRNAs represent a new class of blood biomarkers, directly linked to the multiple biological pathways driving Alzheimer’s disease progression. At Circular Genomics, we’re advancing circRNA innovation to transform how Alzheimer’s is detected and managed. Learn more:…

New results from the U.S. POINTER study show that exercise, healthy eating, brain games, social engagement & regular health check-ups can help protect memory and thinking as we age—regardless of genetics or background. Learn more: na2.hubs.ly/H01lqgD0

Over 7M Americans live with Alzheimer’s today—a number set to nearly double by 2050. The consequences of detecting Alzheimer’s when it is too late will only grow, placing increasing demands on patients, families, and caregivers. The future of Alzheimer's Disease care must include…

Today on National Alzheimer’s Day, we honor patients and caregivers navigating this journey. Early awareness and detection matters—know the signs, seek support, and remember you are not alone. Together, we can advocate for better care and brighter hope.

Encouraging older loved ones to adopt brain-healthy habits—like staying active, eating well, and staying socially engaged—can help protect cognitive function, support independence, and improve quality of life. Learn more: na2.hubs.ly/H0177m60

Our platform leverages the unique biological properties of circular RNA to enable brain-specific diagnostics and therapeutic discovery. By advancing circRNA innovation, we’re bringing the promise of precision medicine closer to patients living with neurological and psychiatric…

We’re excited to announce that our CEO, Paul Sargeant, PhD, will be presenting at LSI Europe ’25! He will discuss how Circular Genomics is advancing precision medicine in neurology and mental health using brain-enriched circular RNA (circRNA) biomarkers.

Alzheimer’s disease touches us all. It affects not only patients, but also the families and caretakers who walk beside them. At Circular Genomics, we are committed to transforming how neurological and psychiatric conditions are diagnosed and managed—bringing hope to those who…

We’ve launched our newly redesigned website! Explore our circular RNA platform and how our technology is shaping the future of precision Neurology and Psychiatry. Visit na2.hubs.ly/y0Gvg80

Finding the right antidepressant for patients with Major Depressive Disorder (MDD) can be complex. The MindLight Antidepressant Response Test™ uses a brain-derived biomarker to help guide treatment decisions by predicting a patient’s likelihood of response and long-term…

When it comes to selecting the right treatment for #MDD patients, pharmacogenomic tests (PGx) only tell part of the story — focusing on how the body metabolizes medications. MindLight uses circular RNA to assess a patient's likelihood of response to SSRIs. Learn more:…

Exciting news from our funded investigators @CircGenomics! Our investment is advancing circRNA, a novel blood-based biomarker for diagnosing and predicting Alzheimer's progression, supported by Diagnostics Accelerators (DxA).

In this week's San Diego Newsletter: Adcentrx gets FDA Orphan Drug nod for gastric cancer drug; @CircGenomics snags $250K for Alzheimer’s RNA test; @iambic_ai + @Rev_Medicine launch partnership; @UCSDExtStudies offers Business of Biotech course. Subscribe: bit.ly/4iqn5b1

Circular Genomics has been awarded a $250K investment from the Alzheimer’s Drug Discovery Foundation to advance our circular RNA blood-based early detection diagnostic testing for Alzheimer’s Disease. Read the full press release here: hubs.la/Q03wdq7H0

🎙️ Hear Dr. Madhukar Trivedi, Professor of Psychiatry at UT Southwestern Medical School, discuss how the MindLight™ Antidepressant Response Test uses circular RNA to help clinicians make more informed treatment decisions — giving patients the best chance at relief, faster.…